Department of Laboratory Medicine and Pathology, NorthShore University HealthSystem, Evanston, Illinois, USA
Department of Pathology, University of New Mexico HSC, Albuquerque, New Mexico, USA.
J Clin Microbiol. 2017 Dec;55(12):3426-3436. doi: 10.1128/JCM.01135-17. Epub 2017 Sep 27.
Nucleic acid amplification tests (NAATs) are reliable tools for the detection of toxigenic from unformed (liquid or soft) stool samples. The objective of this study was to evaluate performance of the cobas Cdiff test on the cobas 4800 system using prospectively collected stool specimens from patients suspected of having infection (CDI). The performance of the cobas Cdiff test was compared to the results of combined direct and broth-enriched toxigenic culture methods in a large, multicenter clinical trial. Additional discrepancy analysis was performed by using the Xpert Epi test. Sample storage was evaluated by using contrived and fresh samples before and after storage at -20°C. Testing was performed on samples from 683 subjects (306 males and 377 females); 113 (16.5%) of 683 subjects were positive for toxigenic by direct toxigenic culture, and 141 of 682 subjects were positive by using the combined direct and enriched toxigenic culture method (reference method), for a prevalence rate of 20.7%. The sensitivity and specificity of the cobas Cdiff test compared to the combined direct and enriched culture method were 92.9% (131/141; 95% confidence interval [CI], 87.4% to 96.1%) and 98.7% (534/541; 95% CI, 97.4% to 99.4%), respectively. Discrepancy analysis using results for retested samples from a second NAAT (Xpert C. difficile/Epi test; Cepheid, Sunnyvale, CA) found no false-negative and 4 false-positive cobas Cdiff test results. There was no difference in positive and negative results in comparisons of fresh and stored samples. These results support the use of the cobas Cdiff test as a robust aid in the diagnosis of CDI.
核酸扩增试验(NAATs)是检测未成形(液体或软)粪便样本中产毒 的可靠工具。本研究的目的是评估 cobas 4800 系统上 cobas Cdiff 试验的性能,该试验使用前瞻性收集的疑似感染 (CDI)患者的粪便标本。cobas Cdiff 试验的性能与直接和肉汤富集产毒培养方法的联合结果在一项大型多中心临床试验中进行了比较。通过 Xpert Epi 测试进行了额外的差异分析。通过在 -20°C 储存前后使用人工和新鲜样本评估样本储存。对 683 名受试者(306 名男性和 377 名女性)的样本进行了检测;113 名(683 名受试者的 16.5%)通过直接产毒培养对产毒 呈阳性,141 名(682 名受试者中的 141 名)通过联合直接和富集产毒培养方法(参考方法)呈阳性,患病率为 20.7%。cobas Cdiff 试验与联合直接和富集培养方法相比的敏感性和特异性分别为 92.9%(131/141;95%置信区间[CI],87.4%至 96.1%)和 98.7%(534/541;95%CI,97.4%至 99.4%)。使用第二种 NAAT(Xpert C. difficile/Epi 测试;Cepheid,Sunnyvale,CA)的复测样本进行差异分析,未发现 cobas Cdiff 试验结果有假阴性和 4 个假阳性。新鲜样本和储存样本的比较中,阳性和阴性结果没有差异。这些结果支持 cobas Cdiff 试验作为 CDI 诊断的可靠辅助手段。